IRF4 destabilized regulatory T cells under inflammatory conditions
In the laboratory, inflammatory signals led human regulatory T cells to lose FOXP3 expression and immune-suppressing function. Deleting an IRF4-controlled element located far from the gene made that shift harder, whereas raising IRF4 together with BATF increased instability. The findings offer a mechanism relevant to cell therapy design, but they demonstrate no benefit in patients.
Science··Midday
Removing the regulatory element made the cells more resistant
Deleting a control region linked to IRF4 made human regulatory T cells less susceptible to inflammation-driven reprogramming. These cells normally restrain immune responses. Without that region, losing FOXP3, a defining protein that preserves their identity, became harder. In the reverse experiment, researchers raised IRF4 together with BATF and observed greater instability, showing that the same molecular connection could influence the process in both directions.[1]
Inflammation changed both cell identity and function
Researchers treated laboratory-grown human regulatory T cells with cytokines found in inflammatory conditions. FOXP3 expression declined, the cells lost their ability to restrain other immune cells, and pro-inflammatory features appeared. The experiment therefore tracked a behavioural shift alongside a change in a genetic marker. The region linked to IRF4 emerged as one control point that allowed this reprogramming to occur.[1]
Cell culture does not demonstrate patient benefit
Preserving regulatory T-cell identity could matter when these cells are manufactured and used as therapies. The work therefore identifies the regulatory element and the IRF4-BATF partnership as possible design targets. Every experiment, however, was performed in cell culture. There are no clinical data showing that removing the element would be safe in patients, that infused cells would remain stable in the body, or that the approach would benefit any disease.[1]
